|
1
|
Spano JP, Busson P, Atlan D, et al:
Nasopharyngeal carcinomas: an update. Eur J Cancer. 39:2121–2135.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Trimeche M, Braham H, Ziadi S, Amara K,
Hachana M and Korbi S: Investigation of allelic imbalances on
chromosome 3p in nasopharyngeal carcinoma in Tunisia: high
frequency of microsatellite instability in patients with
early-onset of the disease. Oral Oncol. 44:775–783. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Razak AR, Siu LL, Liu FF, Ito E,
O’Sullivan B and Chan K: Nasopharyngeal carcinoma: the next
challenges. Eur J Cancer. 46:1967–1978. 2010. View Article : Google Scholar
|
|
5
|
Yoshizaki T: Promotion of metastasis in
nasopharyngeal carcinoma by Epstein-Barr virus latent membrane
protein-1. Histol Histopathol. 17:845–850. 2002.PubMed/NCBI
|
|
6
|
Li S, Rong M and Iacopetta B: DNA
hypermethylation in breast cancer and its association with
clinicopathological features. Cancer Lett. 237:272–280. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wajed SA, Laird PW and DeMeester TR: DNA
methylation: an alternative pathway to cancer. Ann Surg. 234:10–20.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baylin SB and Herman JG: DNA
hypermethylation in tumorigenesis: epigenetics joins genetics.
Trends Genet. 16:168–174. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou J, Cao J, Lu Z, Liu H and Deng D: A
115-bp MethyLight assay for detection of p16 (CDKN2A) methylation
as a diagnostic biomarker in human tissues. BMC Med Genet.
12:672011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Esteller M, Corn PG, Baylin SB and Herman
JG: A gene hypermethylation profile of human cancer. Cancer Res.
61:3225–3229. 2001.PubMed/NCBI
|
|
11
|
Di Vinci A, Perdelli L, Banelli B, et al:
p16INK4a promoter methylation and protein expression in
breast fibroadenoma and carcinoma. Int J Cancer. 114:414–421.
2005.
|
|
12
|
Moher D, Liberati A, Tetzlaff J and Altman
DG; PRISMA Group. Preferred reporting items for systematic reviews
and meta-analyses: the PRISMA statement. Ann Intern Med.
151:264–269. 2009. View Article : Google Scholar
|
|
13
|
Chalmers I: The Cochrane collaboration:
preparing, maintaining, and disseminating systematic reviews of the
effects of health care. Ann NY Acad Sci. 703:156–165. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee S, Kim WH, Jung HY, Yang MH and Kang
GH: Aberrant CpG island methylation of multiple genes in
intrahepatic cholangiocarcinoma. Am J Pathol. 161:1015–1022. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jose S, George PS and Mathew A: Assessment
of confounding and interaction using the mantel-haenszel risk
estimation method. Asian Pac J Cancer Prev. 9:323–325.
2008.PubMed/NCBI
|
|
16
|
Böhning D, Malzahn U, Dietz E, et al: Some
general points in estimating heterogeneity variance with the
DerSimonian-Laird estimator. Biostat. 3:445–457. 2002.PubMed/NCBI
|
|
17
|
Ayadi W, Karray-Hakim H, Khabir A, et al:
Aberrant methylation of p16, DLEC1, BLU and E-cadherin gene
promoters in nasopharyngeal carcinoma biopsies from Tunisian
patients. Anticancer Res. 28:2161–2167. 2008.PubMed/NCBI
|
|
18
|
Ho JH: Stage classification of
nasopharyngeal carcinoma: a review. IARC Sci Publ. 20:99–113.
1978.PubMed/NCBI
|
|
19
|
Rountree MR, Bachman KE, Herman JG and
Baylin SB: DNA methylation, chromatin inheritance, and cancer.
Oncogene. 20:3156–3165. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Widschwendter M and Jones PA: The
potential prognostic, predictive, and therapeutic values of DNA
methylation in cancer. Clin Cancer Res. 8:17–21. 2002.PubMed/NCBI
|
|
21
|
Zou HZ, Yu BM, Wang ZW, et al: Detection
of aberrant p16 methylation in the serum of colorectal cancer
patients. Clin Cancer Res. 8:188–191. 2002.PubMed/NCBI
|
|
22
|
Rocco JW and Sidransky D: p16
(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 264:42–55.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sherr CJ and McCormick F: The RB and p53
pathways in cancer. Cancer Cell. 2:103–112. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
McDermott KM, Zhang J, Holst CR,
Kozakiewicz BK, Singla V and Tlsty TD: p16INK4a prevents
centrosome dysfunction and genomic instability in primary cells.
PLoS Biol. 4:e512006.
|
|
25
|
Zou XP, Zhang B, Zhang XQ, Chen M, Cao J
and Liu WJ: Promoter hypermethylation of multiple genes in early
gastric adenocarcinoma and precancerous lesions. Hum Pathol.
40:1534–1542. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hassler MR, Klisaroska A, Kollmann K, et
al: Antineoplastic activity of the DNA methyltransferase inhibitor
5-aza-2′-deoxycytidine in anaplastic large cell lymphoma.
Biochimie. 94:2297–2307. 2012.
|
|
27
|
Bender CM, Pao MM and Jones PA: Inhibition
of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth
of human tumor cell lines. Cancer Res. 58:95–101. 1998.
|
|
28
|
Tian F, Yip SP, Kwong DL, Lin Z, Yang Z
and Wu VW: Promoter hypermethylation of tumor suppressor genes in
serum as potential biomarker for the diagnosis of nasopharyngeal
carcinoma. Cancer Epidemiol. 37:708–713. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Challouf S, Ziadi S, Zaghdoudi R, Ksiaa F,
Ben Gacem R and Trimeche M: Patterns of aberrant DNA
hypermethylation in nasopharyngeal carcinoma in Tunisian patients.
Clin Chim Acta. 413:795–802. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hutajulu SH, Indrasari SR, Indrawati LP,
et al: Epigenetic markers for early detection of nasopharyngeal
carcinoma in a high risk population. Mol Cancer. 10:482011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tan S, Sun C, Wei X, et al: Quantitative
assessment of lung cancer associated with genes methylation in the
peripheral blood. Exp Lung Res. 39:182–190. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xiang YN and Zhang WY: The clinical
significance of p16 protein non-expression and p16 gene
inactivation by deletions and hypermethylation in nasopharyngeal
carcinoma. Chin J Pathol. 34:358–361. 2005.(In Chinese).
|
|
33
|
Wong TS, Kwong DL, Sham JS, Wei WI, Kwong
YL and Yuen AP: Quantitative plasma hypermethylated DNA markers of
undifferentiated nasopharyngeal carcinoma. Clin Cancer Res.
10:2401–2406. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chang H, Yi B, Li L, et al: Methylation of
tumor associated genes in tissue and plasma samples from liver
disease patients. Exp Mol Pathol. 85:96–100. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tong JH, Tsang RK, Lo KW, et al:
Quantitative Epstein-Barr virus DNA analysis and detection of gene
promoter hypermethylation in nasopharyngeal (NP) brushing samples
from patients with NP carcinoma. Clin Cancer Res. 8:2612–2619.
2002.PubMed/NCBI
|
|
36
|
Kwong J, Lo KW, To KF, Teo PM, Johnson PJ
and Huang DP: Promoter hypermethylation of multiple genes in
nasopharyngeal carcinoma. Clin Cancer Res. 8:131–137.
2002.PubMed/NCBI
|
|
37
|
Lo KW, Cheung ST, Leung SF, et al:
Hypermethylation of the p16 gene in nasopharyngeal carcinoma.
Cancer Res. 56:2721–2725. 1996.PubMed/NCBI
|
